Abstract
Treatment of patients with tuberculosis and HIV infection is complex, with pill burden and treatment adherence presenting major challenges. Rifampicin is a potent inducer of hepatic cytochrome P450 and uridine diphosphate glucuronosyl transferase 1A1 enzymes and the drug efflux pump P-glycoprotein, with potential for major drug–drug interactions with many antiviral drugs. Standard dose raltegravir or efavirenz-based antiretroviral treatment for patients co-infected with HIV and tuberculosis (ANRS 12 300 Reflate TB 2): an open-label, non-inferiority, randomised, phase 3 trialIn patients with HIV given tuberculosis treatment, non-inferiority of raltegravir compared with efavirenz was not shown. Raltegravir was well tolerated and could be considered as an option, but only in selected patients. Full-Text PDF
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
